eligibility_summary
Adults ≥18 with advanced/metastatic NSCLC without actionable EGFR/ALK/ROS1. Cohort1: PD‑1 acquired resistance ≥6 mo, Cohort2: untreated or relapse >6 mo post curative/adjuvant therapy. Need measurable disease, ECOG 0–1, life ≥3 mo, adequate labs/tissue. Exclude prior CCR8/investigational, PD‑1 intolerance, recent systemic therapy, immunosuppression, autoimmune disease, active TB/HBV/HCV/HIV, bleeding/obstruction/effusions, serious cardiac/pulmonary disease or recent thrombosis, anticoagulation.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Interventions: LM-108 + sintilimab (Cohort 1), LM-108 + sintilimab + chemotherapy, then maintenance LM-108 + sintilimab (Cohort 2). Drug types and mechanisms: LM-108 is an investigational monoclonal antibody targeting CCR8, a chemokine receptor enriched on tumor-infiltrating regulatory T cells (Tregs), it is intended to block the CCL1-CCR8 axis and/or deplete CCR8+ Tregs to reduce immunosuppression. Sintilimab is a PD-1–blocking monoclonal antibody (immune checkpoint inhibitor) that restores antitumor T-cell activity. Chemotherapy is standard cytotoxic therapy inducing tumor cell death and may increase antigen release. Cells/pathways targeted: PD-1 pathway on effector T cells, CCR8/CCL1 axis on FOXP3+ Tregs in the tumor microenvironment.